Investors & Media - BrainStorm Cell Therapeutics

News

Press Releases

Month Year

Investor Alerts

Jul 21, 2017

Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative...
Jul 18, 2017

BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with...
Jul 3, 2017

Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has selected Worldwide Clinical Trials...
Jun 14, 2017

BrainStorm to Provide Corporate Update at the BIO International Convention

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the Company will present a corporate...
Jun 13, 2017

BrainStorm Awarded $2.1 Million Non-Dilutive Grant for 2017 by the Israel Innovation Authority

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that its wholly-owned subsidiary, Brainstorm...
- Photos 1
May 22, 2017

BrainStorm to Present at Cell & Gene Exchange Conference in Washington DC

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that the Company will present data from its Phase 2...
- Photos 1
May 16, 2017

BrainStorm Initiated Technology Transfer to City of Hope for U.S. Production of NurOwn® for Phase 3 ALS Study

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has begun training the cell...
- Photos 1
May 15, 2017

BrainStorm Announces First Quarter 2017 Financial Results and Provides Corporate Update

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the first quarter ending March...
- Photos 1
May 1, 2017

BrainStorm to Present at Two Scientific Conferences in May

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the Company will present data from its...
Apr 20, 2017

Brainstorm Cell Therapeutics to Present at ARM's 5th Annual Cell & Gene Therapy Investor Day, April 27 in Boston

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
- Photos 1